APA (7th ed.) Citation

Kunz, J., Schlotmann, A., Daubenbüchel, A., Lobitz, S., Jarisch, A., Grosse, R., . . . Kulozik, A. (2021). Benefits of a disease management program for Sickle Cell Disease in Germany 2011-2019: The increased use of hydroxyurea correlates with a reduced frequency of acute chest syndrome. Journal of Clinical Medicine, 10(19), . https://doi.org/10.3390/jcm10194543

Chicago Style (17th ed.) Citation

Kunz, Joachim, et al. "Benefits of a Disease Management Program for Sickle Cell Disease in Germany 2011-2019: The Increased Use of Hydroxyurea Correlates with a Reduced Frequency of Acute Chest Syndrome." Journal of Clinical Medicine 10, no. 19 (2021). https://doi.org/10.3390/jcm10194543.

MLA (9th ed.) Citation

Kunz, Joachim, et al. "Benefits of a Disease Management Program for Sickle Cell Disease in Germany 2011-2019: The Increased Use of Hydroxyurea Correlates with a Reduced Frequency of Acute Chest Syndrome." Journal of Clinical Medicine, vol. 10, no. 19, 2021, https://doi.org/10.3390/jcm10194543.